Pfizer's tilrekimig shows significant skin clearance in Phase 2 atopic dermatitis study
PFE•Pfizer said its Phase 2 study of tilrekimig met its primary endpoint, with 62.5% of patients receiving 450 mg every two weeks achieving EASI-75 at week 16, versus 19.9% on placebo.
1. Study results
Pfizer said the Phase 2 study met its primary endpoint, showing significant EASI-75 improvement at week 16. Up to 61% of patients in Stage 2 achieved EASI-75, compared with 9.1% on placebo.
2. Safety findings
Pfizer said tilrekimig was well tolerated, with treatment-emergent adverse event rates comparable to placebo, and no serious adverse events related to tilrekimig.
